JP2009544610A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009544610A5 JP2009544610A5 JP2009520782A JP2009520782A JP2009544610A5 JP 2009544610 A5 JP2009544610 A5 JP 2009544610A5 JP 2009520782 A JP2009520782 A JP 2009520782A JP 2009520782 A JP2009520782 A JP 2009520782A JP 2009544610 A5 JP2009544610 A5 JP 2009544610A5
- Authority
- JP
- Japan
- Prior art keywords
- immunization
- drug
- regulatory
- concomitant medication
- drug according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000003053 immunization Effects 0.000 claims 26
- 238000002649 immunization Methods 0.000 claims 26
- 229940124301 concurrent medication Drugs 0.000 claims 11
- 229940079593 drug Drugs 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 11
- 239000002246 antineoplastic agent Substances 0.000 claims 7
- 210000003289 regulatory T cell Anatomy 0.000 claims 7
- 230000001235 sensitizing effect Effects 0.000 claims 7
- 229940000425 combination drug Drugs 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 229940127089 cytotoxic agent Drugs 0.000 claims 5
- 230000006698 induction Effects 0.000 claims 5
- 230000003915 cell function Effects 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 230000002163 immunogen Effects 0.000 claims 4
- 229960001438 immunostimulant agent Drugs 0.000 claims 4
- 239000003022 immunostimulating agent Substances 0.000 claims 4
- 230000003308 immunostimulating effect Effects 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 230000003796 beauty Effects 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 229940044683 chemotherapy drug Drugs 0.000 claims 2
- 229960004397 cyclophosphamide Drugs 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 210000004324 lymphatic system Anatomy 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 108020000411 Toll-like receptor Proteins 0.000 claims 1
- 102000002689 Toll-like receptor Human genes 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 210000003162 effector t lymphocyte Anatomy 0.000 claims 1
- 229960000390 fludarabine Drugs 0.000 claims 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000002452 interceptive effect Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000011277 treatment modality Methods 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83125606P | 2006-07-14 | 2006-07-14 | |
| US86333206P | 2006-10-27 | 2006-10-27 | |
| PCT/US2007/016075 WO2008008541A2 (en) | 2006-07-14 | 2007-07-14 | Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes |
| US11/879,078 US20080014211A1 (en) | 2006-07-14 | 2007-07-14 | Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic and therapeutic purposes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009544610A JP2009544610A (ja) | 2009-12-17 |
| JP2009544610A5 true JP2009544610A5 (https=) | 2010-09-02 |
Family
ID=38922728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009520782A Withdrawn JP2009544610A (ja) | 2006-07-14 | 2007-07-14 | 予防又は治療目的のためにｍｈｃクラスｉ拘束エピトープに対する免疫応答を引き出し、増強し、保持する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080014211A1 (https=) |
| EP (1) | EP2046344A2 (https=) |
| JP (1) | JP2009544610A (https=) |
| AU (1) | AU2007272785A1 (https=) |
| CA (1) | CA2657771A1 (https=) |
| MX (1) | MX2009000452A (https=) |
| WO (1) | WO2008008541A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6977074B2 (en) * | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
| CA2592972A1 (en) * | 2004-12-29 | 2006-07-06 | Mannkind Corporation | Methods to bypass cd+4 cells in the induction of an immune response |
| AU2006259221B8 (en) * | 2005-06-17 | 2013-02-07 | Mannkind Corporation | Multivalent entrain-and-amplify immunotherapeutics for carcinoma |
| SG162817A1 (en) | 2005-06-17 | 2010-07-29 | Mannkind Corp | Methods and compositions.to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma |
| US9486524B2 (en) * | 2006-09-01 | 2016-11-08 | Genticel | Composition for eliciting a specific CTL response, comprising a lympho-ablative compound and a molecule that contains antigenic sequences and targets professional antigen presenting cells |
| AU2010310468A1 (en) * | 2009-10-23 | 2012-05-24 | Mannkind Corporation | Cancer immunotherapy and method of treatment |
| WO2012145671A1 (en) * | 2011-04-20 | 2012-10-26 | The Trustees Of The University Of Pennsylvania | Radioisotope-photodynamic therapy for cancer treatment |
| WO2015014871A1 (en) * | 2013-07-31 | 2015-02-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and kits for identifying effector treg cells |
| EP4237090B1 (en) * | 2020-10-29 | 2026-02-18 | Board of Regents, The University of Texas System | Methods for the detection and treatment of ovarian cancer |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6037135A (en) * | 1992-08-07 | 2000-03-14 | Epimmune Inc. | Methods for making HLA binding peptides and their uses |
| US5747271A (en) * | 1992-12-22 | 1998-05-05 | Ludwig Institute For Cancer Research | Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of HLA-A2/tyrosinase derived peptides, and methods for treating said individuals |
| US5698396A (en) * | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
| US6977074B2 (en) * | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
| US6994851B1 (en) * | 1997-07-10 | 2006-02-07 | Mannkind Corporation | Method of inducing a CTL response |
| US6709844B1 (en) * | 2000-11-16 | 2004-03-23 | Mannkind Corporation | Avoidance of undesirable replication intermediates in plasmid propagation |
| US20030138808A1 (en) * | 1998-02-19 | 2003-07-24 | Simard John J.L. | Expression vectors encoding epitopes of target-associated antigens |
| US6861234B1 (en) * | 2000-04-28 | 2005-03-01 | Mannkind Corporation | Method of epitope discovery |
| US20030215425A1 (en) * | 2001-12-07 | 2003-11-20 | Simard John J. L. | Epitope synchronization in antigen presenting cells |
| DK1276896T3 (da) * | 2000-04-28 | 2010-10-18 | Mannkind Corp | Epitop-synkronisering i antigen-præsenterende celler |
| US6753384B2 (en) * | 2000-07-14 | 2004-06-22 | Metabolix, Inc. | Polyurethanes obtained from hydroxyalkanoates and isocyanates |
| US7252824B2 (en) * | 2001-03-07 | 2007-08-07 | Mannkind Corporation | Anti-neovasculature preparations for cancer |
| WO2003008537A2 (en) * | 2001-04-06 | 2003-01-30 | Mannkind Corporation | Epitope sequences |
| CN101024842A (zh) * | 2001-11-07 | 2007-08-29 | 曼康公司 | 编码靶相关抗原表位的表达载体及其设计方法 |
| AU2003270311A1 (en) * | 2002-09-06 | 2004-03-29 | Mannkind Corporation | Epitope sequences |
| GB0221574D0 (en) * | 2002-09-17 | 2002-10-23 | Isis Innovation | Treatments |
| KR101455222B1 (ko) * | 2002-12-16 | 2014-10-31 | 글로브이뮨 | 면역 요법으로서의 효모계 백신 |
| AU2004249254B2 (en) * | 2003-06-17 | 2010-07-08 | Mannkind Corporation | Combinations of tumor-associated antigens for the treatment of various types of cancers |
| DK1635863T3 (da) * | 2003-06-17 | 2010-11-22 | Mannkind Corp | Sammensætninger til udløsning, forbedring og opretholdelse af immunresponser mod MHC-klasse-i-begrænsede epitoper til profylaktiske eller terapeutiske formål |
| US20060008468A1 (en) * | 2004-06-17 | 2006-01-12 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in diagnostics for various types of cancers |
| US20050287068A1 (en) * | 2004-06-17 | 2005-12-29 | Bot Adrian I | Efficacy of active immunotherapy by integrating diagnostic with therapeutic methods |
| CA2571168A1 (en) * | 2004-06-17 | 2006-01-26 | Mannkind Corporation | Mhc i-binding ssx-241-49 variants |
| US20060159689A1 (en) * | 2004-06-17 | 2006-07-20 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in diagnostics for various types of cancers |
| PL1833506T3 (pl) * | 2004-12-29 | 2016-01-29 | Mannkind Corp | Zastosowanie kompozycji zawierających różne antygeny związane z nowotworem jako szczepionek przeciwnowotworowych |
| JP2008526763A (ja) * | 2004-12-29 | 2008-07-24 | マンカインド コーポレイション | 予防又は治療目的のｍｈｃクラスｉ拘束性エピトープに対する免疫応答の誘導、増強及び保持方法 |
| EP1838338A2 (en) * | 2004-12-29 | 2007-10-03 | Mannkind Corporation | Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs |
| CA2592972A1 (en) * | 2004-12-29 | 2006-07-06 | Mannkind Corporation | Methods to bypass cd+4 cells in the induction of an immune response |
| NZ564359A (en) * | 2005-06-17 | 2011-09-30 | Mannkind Corp | Analogs of pepetides corresponding to class I MHC-restricted T cell epitopes |
| SG162817A1 (en) * | 2005-06-17 | 2010-07-29 | Mannkind Corp | Methods and compositions.to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma |
| AU2006259221B8 (en) * | 2005-06-17 | 2013-02-07 | Mannkind Corporation | Multivalent entrain-and-amplify immunotherapeutics for carcinoma |
| GB0519303D0 (en) * | 2005-09-21 | 2005-11-02 | Oxford Biomedica Ltd | Chemo-immunotherapy method |
-
2007
- 2007-07-14 JP JP2009520782A patent/JP2009544610A/ja not_active Withdrawn
- 2007-07-14 EP EP07810479A patent/EP2046344A2/en not_active Withdrawn
- 2007-07-14 AU AU2007272785A patent/AU2007272785A1/en not_active Abandoned
- 2007-07-14 US US11/879,078 patent/US20080014211A1/en not_active Abandoned
- 2007-07-14 MX MX2009000452A patent/MX2009000452A/es not_active Application Discontinuation
- 2007-07-14 WO PCT/US2007/016075 patent/WO2008008541A2/en not_active Ceased
- 2007-07-16 CA CA002657771A patent/CA2657771A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009544610A5 (https=) | ||
| Frega et al. | Trial Watch: experimental TLR7/TLR8 agonists for oncological indications | |
| Zhang et al. | Advancements of radiotherapy for recurrent head and neck cancer in modern era | |
| Pol et al. | Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy | |
| Garbe et al. | Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting | |
| Wu et al. | INSPIRE: a phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer | |
| Confino et al. | Inhibition of mouse breast adenocarcinoma growth by ablation with intratumoral alpha-irradiation combined with inhibitors of immunosuppression and CpG | |
| Wang et al. | BNCT for locally recurrent head and neck cancer: preliminary clinical experience from a phase I/II trial at Tsing Hua open-pool reactor | |
| JP2013536157A5 (https=) | ||
| JP2010529026A5 (https=) | ||
| Gunderson et al. | Exploring optimal sequencing of radiation and immunotherapy combinations | |
| JP2006506441A5 (https=) | ||
| NZ601677A (en) | Improved cancer therapy based on tumor associated antigens derived from cyclin d1 | |
| Bergman | Cancer immunotherapy | |
| JP2021534094A5 (https=) | ||
| JP2011103891A5 (https=) | ||
| Domankevich et al. | RIG-1-like receptor activation synergizes with intratumoral alpha radiation to induce pancreatic tumor rejection, triple-negative breast metastases clearance, and antitumor immune memory in mice | |
| Nadella et al. | Emerging neo adjuvants for harnessing therapeutic potential of M1 tumor associated macrophages (TAM) against solid tumors: Enusage of plasticity | |
| JP2016526531A5 (https=) | ||
| JP2019531293A5 (https=) | ||
| CN103110939A (zh) | 诱导肿瘤特异性免疫的疫苗及其应用 | |
| Schneble et al. | Breast cancer immunotherapy | |
| Fujimoto et al. | Overcoming immunotherapy resistance and inducing abscopal effects with boron neutron immunotherapy (B‐NIT) | |
| Lee et al. | S-1 based doublet as an adjuvant chemotherapy for curatively resected stage III gastric cancer: results from the randomized phase III POST trial | |
| Wang et al. | rWTC‐MBTA vaccine induces potent adaptive immune responses against glioblastomas via dynamic activation of dendritic cells |